{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "G",
          "alt": "R",
          "position": "2385"
        },
        "variant_string_id": "LRRK2 G2385R"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Parkinson disease (PD) is characterized by loss of dopaminergic neurons in the substantia nigra, and LRRK2 mutations are associated with increased kinase activity leading to toxic gain of function and higher apoptotic cell death in dopaminergic cell lines.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism of PD as involving loss of dopaminergic neurons and links LRRK2 mutations to increased kinase activity and toxicity, which is relevant to the functional assay."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "In vitro kinase assays were performed to measure autophosphorylation and phosphorylation of myelin basic protein (MBP) by LRRK2 variants, reflecting the kinase activity associated with PD pathogenesis.",
          "judgment": "Yes",
          "reasoning": "The kinase assay directly measures the enzymatic activity of LRRK2, which is implicated in PD pathogenesis through toxic gain of function, making this class of assay applicable.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Control assays included wild-type (WT) LRRK2 and vector control, with established kinases for validation. Experiments were performed with n=4 replicates as indicated in histograms (Fig. 3C and 3E).",
          "judgment": "Yes",
          "reasoning": "Both normal (WT) and negative (vector) controls were used, and replicates (n=4) were explicitly mentioned, satisfying the criteria for basic controls and replicates.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "The assay included the known pathogenic variant p.G2019S as a positive control alongside other variants (Fig. 3A).",
          "judgment": "Yes",
          "reasoning": "The inclusion of p.G2019S, a well-established pathogenic variant, as a control meets the requirement for variant controls.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "Statistical significance was reported for kinase activity differences (p<0.05 for p.G2385R compared to WT) in Fig. 3C, but no direct OddsPath calculation was provided.",
          "judgment": "No",
          "reasoning": "While p-values are provided, there is no direct calculation or estimation of OddsPath for pathogenicity likelihood from the functional data.",
          "next_step_or_outcome": "Proceed to Step 4b"
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study tested multiple variants including p.G2019S (pathogenic), p.R1398H (protective), p.R1628P, p.S1647T, and p.G2385R, totaling more than 11 variants across the assays.",
          "judgment": "At least 11",
          "reasoning": "More than 11 variants were tested in the study, including both pathogenic and benign controls, meeting the threshold for moderate evidence strength.",
          "next_step_or_outcome": "Max PS3_moderate"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "The functional evidence for LRRK2 p.G2385R supports a pathogenic role with moderate strength (PS3_moderate) due to increased kinase activity compared to wild-type, validated controls and replicates, and testing of more than 11 variants, despite the absence of direct OddsPath calculation."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "R",
          "alt": "P",
          "position": "1628"
        },
        "variant_string_id": "LRRK2 R1628P"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Parkinson disease (PD) is characterized by loss of dopaminergic neurons in the substantia nigra, and LRRK2 mutations are associated with increased kinase activity leading to toxic gain of function and higher apoptotic cell death in dopaminergic cell lines.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism of PD as involving loss of dopaminergic neurons and links LRRK2 mutations to increased kinase activity and toxicity, which is relevant to the functional assay."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "In vitro kinase assays were performed to measure autophosphorylation and phosphorylation of myelin basic protein (MBP) by LRRK2 variants, reflecting the kinase activity associated with PD pathogenesis.",
          "judgment": "Yes",
          "reasoning": "The kinase assay directly measures the enzymatic activity of LRRK2, which is implicated in PD pathogenesis through toxic gain of function, making this class of assay applicable.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Control assays included wild-type (WT) LRRK2 and vector control, with established kinases for validation. Experiments were performed with n=4 replicates as indicated in histograms (Fig. 3C and 3E).",
          "judgment": "Yes",
          "reasoning": "Both normal (WT) and negative (vector) controls were used, and replicates (n=4) were explicitly mentioned, satisfying the criteria for basic controls and replicates.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "The assay included the known pathogenic variant p.G2019S as a positive control alongside other variants (Fig. 3A).",
          "judgment": "Yes",
          "reasoning": "The inclusion of p.G2019S, a well-established pathogenic variant, as a control meets the requirement for variant controls.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "Statistical significance was reported for kinase activity differences (p=0.07 for p.R1628P compared to WT) in Fig. 3C, but no direct OddsPath calculation was provided.",
          "judgment": "No",
          "reasoning": "While p-values are provided, there is no direct calculation or estimation of OddsPath for pathogenicity likelihood from the functional data.",
          "next_step_or_outcome": "Proceed to Step 4b"
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study tested multiple variants including p.G2019S (pathogenic), p.R1398H (protective), p.R1628P, p.S1647T, and p.G2385R, totaling more than 11 variants across the assays.",
          "judgment": "At least 11",
          "reasoning": "More than 11 variants were tested in the study, including both pathogenic and benign controls, meeting the threshold for moderate evidence strength.",
          "next_step_or_outcome": "Max PS3_moderate"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "The functional evidence for LRRK2 p.R1628P supports a pathogenic role with moderate strength (PS3_moderate) due to increased kinase activity compared to wild-type, validated controls and replicates, and testing of more than 11 variants, despite the absence of direct OddsPath calculation."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "R",
          "alt": "H",
          "position": "1398"
        },
        "variant_string_id": "LRRK2 R1398H"
      },
      "functional_evidence_aim": "Benign",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Parkinson disease (PD) is characterized by loss of dopaminergic neurons in the substantia nigra, and LRRK2 mutations are associated with increased kinase activity leading to toxic gain of function, while reduced kinase activity may be protective.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism of PD and suggests that reduced kinase activity in LRRK2 could be protective, relevant to the functional assay for this variant."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "In vitro kinase assays were performed to measure autophosphorylation and phosphorylation of myelin basic protein (MBP) by LRRK2 variants, reflecting the kinase activity associated with PD pathogenesis.",
          "judgment": "Yes",
          "reasoning": "The kinase assay directly measures the enzymatic activity of LRRK2, which is implicated in PD pathogenesis, and reduced activity is hypothesized to be protective, making this class of assay applicable.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Control assays included wild-type (WT) LRRK2 and vector control, with established kinases for validation. Experiments were performed with n=4 replicates as indicated in histograms (Fig. 3C and 3E).",
          "judgment": "Yes",
          "reasoning": "Both normal (WT) and negative (vector) controls were used, and replicates (n=4) were explicitly mentioned, satisfying the criteria for basic controls and replicates.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "The assay included the known pathogenic variant p.G2019S as a positive control alongside other variants (Fig. 3A).",
          "judgment": "Yes",
          "reasoning": "The inclusion of p.G2019S, a well-established pathogenic variant, as a control meets the requirement for variant controls, even in the context of assessing a benign variant.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "Statistical significance was reported for kinase activity differences (p<0.001 for p.R1398H compared to WT, showing reduced activity) in Fig. 3C and 3E, but no direct OddsPath calculation was provided.",
          "judgment": "No",
          "reasoning": "While p-values are provided, there is no direct calculation or estimation of OddsPath for benign likelihood from the functional data.",
          "next_step_or_outcome": "Proceed to Step 4b"
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study tested multiple variants including p.G2019S (pathogenic), p.R1398H (protective), p.R1628P, p.S1647T, and p.G2385R, totaling more than 11 variants across the assays.",
          "judgment": "At least 11",
          "reasoning": "More than 11 variants were tested in the study, including both pathogenic and benign controls, meeting the threshold for moderate evidence strength.",
          "next_step_or_outcome": "Max BS3_moderate"
        }
      ],
      "final_evidence_strength": {
        "type": "Benign",
        "strength": "BS3_moderate"
      },
      "overall_conclusion": "The functional evidence for LRRK2 p.R1398H supports a benign/protective role with moderate strength (BS3_moderate) due to significantly reduced kinase activity compared to wild-type, validated controls and replicates, and testing of more than 11 variants, despite the absence of direct OddsPath calculation."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "S",
          "alt": "T",
          "position": "1647"
        },
        "variant_string_id": "LRRK2 S1647T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Parkinson disease (PD) is characterized by loss of dopaminergic neurons in the substantia nigra, and LRRK2 mutations are associated with increased kinase activity leading to toxic gain of function and higher apoptotic cell death in dopaminergic cell lines.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism of PD as involving loss of dopaminergic neurons and links LRRK2 mutations to increased kinase activity and toxicity, which is relevant to the functional assay."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "In vitro kinase assays were performed to measure autophosphorylation and phosphorylation of myelin basic protein (MBP) by LRRK2 variants, reflecting the kinase activity associated with PD pathogenesis.",
          "judgment": "Yes",
          "reasoning": "The kinase assay directly measures the enzymatic activity of LRRK2, which is implicated in PD pathogenesis through toxic gain of function, making this class of assay applicable.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Control assays included wild-type (WT) LRRK2 and vector control, with established kinases for validation. Experiments were performed with n=4 replicates as indicated in histograms (Fig. 3C and 3E).",
          "judgment": "Yes",
          "reasoning": "Both normal (WT) and negative (vector) controls were used, and replicates (n=4) were explicitly mentioned, satisfying the criteria for basic controls and replicates.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "The assay included the known pathogenic variant p.G2019S as a positive control alongside other variants (Fig. 3A).",
          "judgment": "Yes",
          "reasoning": "The inclusion of p.G2019S, a well-established pathogenic variant, as a control meets the requirement for variant controls.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "No significant difference in kinase activity for p.S1647T compared to WT was reported (Fig. 3C and 3E), and no direct OddsPath calculation was provided.",
          "judgment": "No",
          "reasoning": "There is no significant functional impact reported for p.S1647T compared to WT, and no OddsPath calculation or estimation is provided.",
          "next_step_or_outcome": "Proceed to Step 4b"
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study tested multiple variants including p.G2019S (pathogenic), p.R1398H (protective), p.R1628P, p.S1647T, and p.G2385R, totaling more than 11 variants across the assays.",
          "judgment": "At least 11",
          "reasoning": "More than 11 variants were tested in the study, including both pathogenic and benign controls, meeting the threshold for moderate evidence strength. However, the lack of functional impact limits the evidence strength.",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The functional evidence for LRRK2 p.S1647T supports a pathogenic role with only supporting strength (PS3_supporting) due to no significant difference in kinase activity compared to wild-type, despite validated controls, replicates, and testing of more than 11 variants."
    }
  ]
}